Fecal Serine Protease Profiling in Inflammatory Bowel Diseases

Jablaoui, Amin; Kriaa, Aïcha; Mkaouar, Héla; Akermi, Nizar; Soussou, Souha; Wysocka, Magdalena; Wołoszyn, Dominika; Amouri, A.; Gargouri, Ali; Maguin, Emmanuelle; Lesner, Adam; Rhimi, Moez

doi:10.3389/fcimb.2020.00021

Cited by 70 publications

(72 citation statements)

References 28 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with these data, we have recently revealed a consistent proteomic profile of active serine proteases from IBD and healthy fecal samples 159 . Interestingly, the functional analysis of these fecal proteolytic activities has unveiled unique active proteases from IBD fecal samples This approach has identified not only proteases previously known as potential candidates in IBD pathophysiology, but also enzymes not yet described in this setting 159 . Covalent ABP were also designed for trypsin‐like enzymes and consequently suggested as promising tools to monitor such activities in their natural environment 160 .…”

Section: Achieving Specificity: Tools Assessing Serine Protease Activsupporting

confidence: 81%

Serine proteases at the cutting edge of IBD: Focus on gastrointestinal inflammation

et al. 2020

Self Cite

View full text Add to dashboard Cite

Serine proteases have been long recognized to coordinate many physiological processes and play key roles in regulating the inflammatory response. Accordingly, their dysregulation has been regularly associated with several inflammatory disorders and suggested as a central mechanism in the pathophysiology of digestive inflammation. So far, studies addressing the proteolytic homeostasis in the gut have mainly focused on host serine proteases as candidates of interest, while largely ignoring the potential contribution of their bacterial counterparts. The human gut microbiota comprises a complex ecosystem that contributes to host health and disease. Yet, our understanding of microbially produced serine proteases and investigation of whether they are causally linked to IBD is still in its infancy. In this review, we highlight recent advances in the emerging roles of host and bacterial serine proteases in digestive inflammation. We also discuss the application of available tools in the gut to monitor disease‐related serine proteases. An exhaustive representation and understanding of such functional potential would help in closing existing gaps in mechanistic knowledge.

show abstract

Section: Achieving Specificity: Tools Assessing Serine Protease Activsupporting

confidence: 81%

Serine proteases at the cutting edge of IBD: Focus on gastrointestinal inflammation

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Activation of the S protein via proeolytic cleavage is controlled by host trypsin-like proteases, whose activity is upregulated in IBD, and this effect might facilitate infection in patients with IBD. 42 Collectively, these findings suggested the possibility that patients with IBD might be particularly susceptible to covid-19. However, there is no evidence so far that patients with IBD are highly susceptible to covid-19.…”

Section: Covid-19 and Ibdmentioning

confidence: 98%

COVID-19 and immunomodulation in IBD

Neurath

2020

Gut

261

310

View full text Add to dashboard Cite

The current coronavirus pandemic is an ongoing global health crisis due to COVID-19, caused by severe acute respiratory syndrome coronavirus 2. Although COVID-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to COVID-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of COVID-19. Here, the current understanding of the pathophysiology of COVID-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed.

show abstract

“…39 Moreover, the serine protease level, the key primer to activate S-protein is 10 times higher in patients with IBD than others. 40 Both these factors contribute to enhanced viral attachment to the host cell and thus, increased infection and (2) IBD patients who are already on immunosuppressive medications may be at a higher risk of infection. In fact, active disease with thiopurines has been shown to increase the infection potential.…”

Section: Inflammatory Bowel Diseasementioning

confidence: 99%

2019 Novel Coronavirus Infection: Gastrointestinal Manifestations

Samanta

Dhar

Kochhar

2020

Journal of Digestive Endoscopy

View full text Add to dashboard Cite

The world is witnessing a major public health crisis in the wake of the third coronavirus strain pandemic, a novel coronavirus (severe acute respiratory syndrome coronavirus 2). Although initially thought to be a pure respiratory pathogen, recent reports have highlighted not only the extrapulmonary effects of the virus but also, importantly, the gastrointestinal tract (GIT) effects. Various studies have looked into the effects of this novel coronavirus infection (coronavirus-19 disease [COVID-19]) on GIT involvement with reports of more frequent involvement than previously expected. With feco-oral transmission, debate being conclusively proven with fecal samples testing positive for COVID-19 and longer shedding time, it only underlines the importance of GIT involvement. Moreover, the presence of other GI diseases, such as inflammatory bowel disease, with COVID-19 infection might wreak havoc leading to poor patient outcomes.

show abstract

Fecal Serine Protease Profiling in Inflammatory Bowel Diseases

Cited by 70 publications

References 28 publications

Serine proteases at the cutting edge of IBD: Focus on gastrointestinal inflammation

Serine proteases at the cutting edge of IBD: Focus on gastrointestinal inflammation

COVID-19 and immunomodulation in IBD

2019 Novel Coronavirus Infection: Gastrointestinal Manifestations

Contact Info

Product

Resources

About